{"id":"W2073369621","doi":"10.1007/s10637-005-5862-9","title":"A phase II trial of ZD1839 (Iressa™) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer","year":2005,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":false,"ca_institutions":"AstraZeneca (Canada); Jewish General Hospital; Ottawa Regional Cancer Foundation; Cancer Care Ontario","funders":"","keywords":"Medicine; Internal medicine; Colorectal cancer; Adverse effect; Rash; Cancer; Oncology; Nausea; Tolerability; Chemotherapy; Gastroenterology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009606758,0.001389126,0.002226341,0.0005156381,0.000430397,0.00071928,0.0006501324,0.0009898527,0.003649394],"category_scores_gemma":[0.0008611103,0.0005000234,0.001000411,0.0004986146,0.0009085152,0.0007937296,0.0002519464,0.002998662,0.0008066061],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008193612,"about_ca_system_score_gemma":0.001269774,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001701324,"about_ca_topic_score_gemma":0.005075675,"domain_scores_codex":[0.9997889,0.00009135393,0.00001034012,0.00003497463,0.00001914108,0.00005518962],"domain_scores_gemma":[0.9995102,0.00009343346,0.00005913746,0.0000292455,0.00002317805,0.0002848594],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8685768,0.02058028,0.004041714,0.0006826501,0.0009908834,0.0002754401,0.0001897808,0.001939996,0.02064134,0.0003728233,0.005736889,0.07597134],"study_design_scores_gemma":[0.8286327,0.1585365,0.007381239,0.00002309086,0.0003479921,0.0002177622,0.00005036303,0.0007811504,0.001287359,0.000176504,0.002541962,0.00002348616],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9890661,0.003594927,0.0005000499,0.001205943,0.0003945815,0.001343878,0.001345498,0.0001128198,0.002436002],"genre_scores_gemma":[0.9835707,0.004234549,0.001581452,0.001232833,0.0003383432,0.001032155,0.003187013,0.00003006886,0.004792904],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003649394,"threshold_uncertainty_score":0.0122084,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02695445011454185,"score_gpt":0.3051791641472074,"score_spread":0.2782247140326655,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}